NeRRe Therapeutics
PrivateLast Round
Series B
Extension
Jul 7, 2021
Total Funding Raised
$74.73M
Company Overview
NeRRe Therapeutics is a clinical-stage biotechnology company that develops a portfolio of neurokinin receptor antagonists to treat debilitating conditions caused by neuronal hypersensitivity.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
NeRRe Therapeutics Comparables
Compare NeRRe Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Axalbion | 85% | |
| Nocion Therapeutics | 81% | |
| Melius Pharma | 79% |
NeRRe Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Jul 7, 2021 | ||||
| Series B | Jan 5, 2017 | ||||
| Series A | Dec 19, 2012 |
Key People
Founding team and executive leadership
NeRRe Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Forbion Capital Partners | Series B Extension, Series B |
| Forbion | Series B Extension, Series B |
| Future Fund | Series B Extension |
| Advent Life Sciences | Series B Extension, Series B |
| Fountain Healthcare Partners | Series B Extension, Series B |
| OrbiMed | Series B Extension, Series B |
| Advent Venture Partners | Series A |
NeRRe Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about NeRRe Therapeutics's valuation, stock price, and market status.
Is NeRRe Therapeutics a public or private company?
NeRRe Therapeutics is a private company.
What is the current stock price of NeRRe Therapeutics?
NeRRe Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is NeRRe Therapeutics worth (valuation)?
Valuation information for NeRRe Therapeutics is not publicly available.
Can I buy NeRRe Therapeutics stock?
NeRRe Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was NeRRe Therapeutics's last funding round?
NeRRe Therapeutics's most recent funding round was Series B Extension on July 7, 2021.
Who are the main investors in NeRRe Therapeutics?
Key investors in NeRRe Therapeutics include Columbus Venture Partners.
Will NeRRe Therapeutics IPO soon?
No public IPO plans have been announced for NeRRe Therapeutics.
How can I track NeRRe Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor NeRRe Therapeutics's secondary market activity and sign up for updates.